<DOC>
	<DOCNO>NCT02338271</DOCNO>
	<brief_summary>1 . Subject : 10 patient : Chronic low back pain patient lumbar intervertebral disc degeneration 2 . Investigational Product : Autologous adipose derive mesenchymal stem cell plus hyaluronic acid derivative ( Tissuefill ) 3 . Time frame - 1 year</brief_summary>
	<brief_title>Autologous Adipose Derived Stem Cell Therapy Intervertebral Disc Degeneration</brief_title>
	<detailed_description>1 . Purpose Clinical Study : To transplant autologous adipose derive mesenchymal stem cell hyaluronic acid patient chronic low back pain cause degenerative lumbar disc examine procedure 's safety efficacy . 2 . Phases Design Clinical Study : This clinical study I/IIa phase single-group , open , investigator initiate trial . 3 . Investigational Product : Autologous adipose derive mesenchymal stem cell separate subject ( 2 x 10^7 cells/mL /vial 4 x 10^7 cells/mL /vial ) . The investigational product mixed 1 mL concomitant drug Tissuefill ( hyaluronic acid derivative , Cha Meditech Co. , Ltd. ) . 4 . Inclusion Criteria 1 . Males female subject age 18 less 70 . 2 . Subjects experience pain lower back buttock fail respond conservative therapy perform period 3 month longer . 3 . Oswestry Disability Index 30 % high . 4 . Visual Analogue Scale 4 high . 5 . Subjects receive Magnetic Resonance Imaging ( hereinafter refer MRI ) assessment grade 3 4 Lumbar 1 - Sacral 1 , accord Pfirrmann grading system . 6 . Subjects assess similar degree pain usual discogram perform degenerative lumbar disc ( ) identify MRI , one two disc cause concordant pain . 7 . Subjects sign informed consent form stem cell transplantation therapy . 5 . Exclusion Criteria 1 . Subjects severe lumbar stenosis herniated nucleus pulposus lumbar exhibit symptom nerve compression require surgery . 2 . Subjects spinal instability , spondylitis , vertebral fracture 3 . Patients severe intervertebral disc degeneration result reduction disc height ½ . 4 . Subjects severe osteoporosis ( average T-score -2.5 lumbar bone density test ) 5 . Patients receive intra-discal procedure stem cell therapy injection steroid disc surgery discectomy disc cell transplantation plan perform . 6 . Patients receive lumbar epidural steroid injection within week prior cell transplantation . 7 . Subjects hypersensitive sodium hyaluronate . 8 . Pregnant breastfeed woman 9 . Female patient possibility pregnancy period clinical study use medically acceptable method contraception . 10 . Subjects mental illness drug alcohol addiction subject incapable understand purpose method clinical study . 11 . Subjects participate another clinical study 30 day prior study . 12 . Subjects severe medical disease ( hypertension unresponsive drug treatment , diabetes unresponsive drug treatment , hepatocirrhosis , renal failure , tumor ) affect outcome clinical study . 13 . Subjects clinically significant finding render subject unsuitable clinical study , judge investigator responsible clinical study . 6 . Dosage Administration : The autologous adipose derive mesenchymal stem cell investigational product ( 2 x 10^7 cells/mL /vial 4 x 10^7 cells/mL /vial ) Tissuefill 1mL/syringe supply operating room . The investigational product Tissuefill ( hyaluronic acid derivative ) mix place 22 G syringe . A single dosage 2ⅹ10^7 autologous adipose derive mesenchymal stem cell per person administer 5 subject , single dosage 4ⅹ10^7 cell per person administer 5 subject , inject center nucleus pulposus . 7 . Primary Endpoint : Evaluation Safety Tolerability The transplantation consider safe tolerable , absence follow type counterevidence . - Adverse event grade 3 ( NCI grade system ) relate cell products/ evidence cell contaminate pollutant / evidence cell exhibit tumorigenic potential 8 . Secondary Endpoint 1 . Change T2 MRI signal intensity nucleus pulposus autologous adipose derive mesenchymal stem cell 6 12 month transplantation compare transplantation 2 . Change VAS 1 , 3 , 6 , 9 , 12 month transplantation autologous adipose derive mesenchymal stem cell , compare transplantation 3 . Change ODI 1 , 3 , 6 , 9 , 12 month transplantation autologous adipose derive mesenchymal stem cell , compare transplantation 4 . Change Short Form ( SF ) -36 1 , 3 , 6 , 9 , 12 month transplantation autologous adipose derive mesenchymal stem cell , compare transplantation 5 . Assessment overall improvement Disc Height Index ( hereinafter refer DHI ) 6 12 month transplantation autologous adipose derive mesenchymal stem cell , compare transplantation</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Subjects experience pain lower back buttock fail respond conservative therapy perform period 3 month longer . 2 . Oswestry Disability Index 30 % high . 3 . Visual Analogue Scale 4 high . 4 . Subjects receive Magnetic Resonance Imaging ( hereinafter refer MRI ) assessment grade 3 4 Lumbar 1 Sacral 1 , accord Pfirrmann grading system . 5 . Subjects assess similar degree pain usual discogram perform degenerative lumbar disc ( ) identify MRI , one two disc cause pain . 6 . Subjects sign informed consent form stem cell transplantation therapy . 1 . Subjects severe lumbar stenosis herniated nucleus pulposus lumbar exhibit symptom nerve compression require surgery . 2 . Subjects spinal instability , spondylitis , vertebral fracture 3 . Patients severe intervertebral disc degeneration result reduction disc height ½ . 4 . Subjects severe osteoporosis ( average Tscore 2.5 lumbar bone density test ) 5 . Patients receive intradiscal procedure stem cell therapy injection steroid disc surgery discectomy disc cell transplantation plan perform . 6 . Patients receive lumbar epidural steroid injection within week prior cell transplantation . 7 . Subjects hypersensitive sodium hyaluronate . 8 . Pregnant breastfeed woman 9 . Female patient possibility pregnancy period clinical study use medically acceptable method contraception . * Medically acceptable method contraception : condom , oral contraceptive administer continually least 3 month , implantable contraceptive surgically insert 3 month prior clinical study , inject inserted contraceptive , intrauterine contraceptive device , etc . 10 . Subjects mental illness drug alcohol addiction subject incapable understand purpose method clinical study . 11 . Subjects participate another clinical study 30 day prior study . 12 . Subjects severe medical disease ( hypertension unresponsive drug treatment , diabetes unresponsive drug treatment , hepatocirrhosis , renal failure , tumor ) affect outcome clinical study . 13 . Subjects clinically significant finding render subject unsuitable clinical study , judge investigator responsible clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Low back pain</keyword>
	<keyword>Mesenchymal stromal stem cell</keyword>
	<keyword>Hyaluronic acid</keyword>
</DOC>